Positive
●
Proactive Investors
●
17 days ago
Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with Merck chief medical officer Eliav Barr, who conveyed confidence in the company's pipeline, with oncology and oth...